Rumor: AstraZeneca could be weighing Cubist buyout

The Telegraph reported on some fresh takeover rumors last night, noting new gossip that British drugmaker AstraZeneca ($AZN) is considering a buyout of Lexington, MA-based Cubist Pharmaceuticals ($CBST), which offers potential suitors immediate additional cash flow from its top-selling antibiotic for complicated skin and MRSA infections, Cubicin. The antibiotic brought in nearly $600 million in sales last year, and some analysts think the drug might be destined for blockbuster status. AstraZeneca, which has a license to the antibiotic for the Chinese market, presumably knows the group at Cubist quite well. But we'll see whether the rumor mill proves correct on this one. Report

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.